Evaluation of the immune-profiling for patients participating in Phase Ib/II Study of BBI608 in Combination with Pembrolizumab and the relationship between the immune-profiling and efficacy using paired biopsies and peripheral blood.
Not Applicable
- Conditions
- metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000024500
- Lead Sponsor
- ational Cancer Center Hospital East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 59
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients who are unfit for the study as determined by the attending physician
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method